Innovation in Pediatric Drugs Act of 2024
Latest Action
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S5685-5686)
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Innovation in Pediatric Drugs Act of 2024 is a Senate bill introduced in the 118th Congress aimed at addressing issues related to pediatric drug development. The bill was read twice and referred to the Senate Committee on Health, Education, Labor, and Pensions but did not advance further and is currently classified as failed or expired. No official summary or full text of the bill is publicly available, limiting detailed analysis of its provisions. The bill falls under the health policy area, suggesting its focus on improving innovation or regulatory processes for drugs intended for children.
This bill sought to promote innovation in pediatric drug development but did not progress beyond committee referral and is now expired, with limited public information on its specific provisions.
- Introduced in the Senate during the 118th Congress as S.4905.
- Referred to the Committee on Health, Education, Labor, and Pensions after initial readings.
- No official summary or full text available, limiting detailed understanding of the bill's content.
['Pediatric patients who require specialized drug treatments', 'Pharmaceutical companies involved in pediatric drug research and development', 'Health care providers focusing on pediatric care', 'Regulatory agencies overseeing drug approval processes']
['Lack of publicly available full text and summary restricts transparency and informed public debate.', 'Unclear implementation mechanisms and funding sources due to missing bill text.', 'Potential challenges in oversight and enforcement cannot be assessed without detailed provisions.']
The bill was introduced in the Senate and referred to the relevant health committee but did not advance further, indicating limited legislative momentum. It is situated within ongoing congressional efforts to address pediatric drug development challenges, a recognized area within health policy.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Potential stimulation of pediatric drug research and development if provisions included incentives or regulatory changes.', 'Possible shifts in pharmaceutical industry focus toward pediatric treatments.', 'Impacts on healthcare providers through changes in drug availability or approval processes.']
The absence of an official summary and full bill text highlights a transparency gap that limits public understanding and oversight. Monitoring future legislative efforts in this area should prioritize availability of complete documentation to enable thorough analysis and accountability.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.